Surendra Kumar Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Surendra Kumar Sharma has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Vishwanath Upadhyay
Senior Scientist Fellow, National Academy of Sciences, India (NASI)
10 shared publicationsAlladi Mohan
Department of Medicine, Sri Venkateswara Institute of Medical Sciences
6 shared publications- Achintya Dinesh Singh
Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
3 shared publications Binit Kumar Singh
Department of Internal Medicine, All India Institute of Medical Sciences, New Delhi, India
3 shared publicationsPrahlad Kumar
National Tuberculosis Institute, Bengaluru, Karnataka, India
3 shared publicationsRohini Sharma
Department of Internal Medicine, All India Institute of Medical Sciences, New Delhi, India
3 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 39 (5) , 339-340
Jagdev Singh Guleria ( 14 December 1927–22 January 2026 )
Jagdev Singh Guleria (14 December 1927–22 January 2026)
- 20 August 2026
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 39 (5) , 339-340
Open AccessJagdev Singh Guleria ( 14 December 1927–22 January 2026 )
Jagdev Singh Guleria (14 December 1927–22 January 2026)
- Open Access
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1717909
From anonymity to stardom: history of nontuberculous mycobacterial disease in humans
Until recently, nontuberculous mycobacteria (NTM) were not considered as human pathogens. Their nomenclature has evolved over several years, until 1971 when finally named as NTM, which is universally accepted now. Because of continuously evolving diagnostic methods, several new species/subspecies of NTM were identified. Presently, nearly 200 NTM species have been reported. Similar to tuberculosis (TB), NTM are known to involve both pulmonary and extrapulmonary organs. Diagnosis of NTM disease is quite cumbersome and is primarily based on their growth characteristics on solid and liquid cultures. Biochemical testing was the mainstay of NTM diagnosis and species identification in the past, which was often erroneous. Recently, molecular tests like line probe assay, targeted, and whole genome sequencing have become available for rapid and accurate diagnosis. Isolation and identification of NTM species/subspecies alone do not warrant treatment. After ascertaining clinical relevance, virulence of NTM species, and evidence for clinical and radiological progression, the decision to administer treatment is taken. Multiple drugs are often administered for 12 months after sputum culture conversion, except in M. kansasii , and M. szulgai , where this constitutes the total treatment duration, with careful follow‑up for relapse and exogenous new infection. The present review traces the history, evolution of classification of NTM, strides made in the diagnosis and treatment of NTM disease. By integrating these historical lessons on taxonomy, culture phenotypes, genotypes and diagnostic pitfalls with contemporary molecular tools and species/subspecies specific treatment regimens, current practice enables more precise, timely, and patient−centered management of NTM disease.
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1717909
Open AccessFrom anonymity to stardom: history of nontuberculous mycobacterial disease in humans
Until recently, nontuberculous mycobacteria (NTM) were not considered as human pathogens. Their nomenclature has evolved over several years, until 1971 when finally named as NTM, which is universally accepted now. Because of continuously evolving diagnostic methods, several new species/subspecies of NTM were identified. Presently, nearly 200 NTM species have been reported. Similar to tuberculosis (TB), NTM are known to involve both pulmonary and extrapulmonary organs. Diagnosis of NTM disease is quite cumbersome and is primarily based on their growth characteristics on solid and liquid cultures. Biochemical testing was the mainstay of NTM diagnosis and species identification in the past, which was often erroneous. Recently, molecular tests like line probe assay, targeted, and whole genome sequencing have become available for rapid and accurate diagnosis. Isolation and identification of NTM species/subspecies alone do not warrant treatment. After ascertaining clinical relevance, virulence of NTM species, and evidence for clinical and radiological progression, the decision to administer treatment is taken. Multiple drugs are often administered for 12 months after sputum culture conversion, except in M. kansasii , and M. szulgai , where this constitutes the total treatment duration, with careful follow‑up for relapse and exogenous new infection. The present review traces the history, evolution of classification of NTM, strides made in the diagnosis and treatment of NTM disease. By integrating these historical lessons on taxonomy, culture phenotypes, genotypes and diagnostic pitfalls with contemporary molecular tools and species/subspecies specific treatment regimens, current practice enables more precise, timely, and patient−centered management of NTM disease.
- 15 July 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 57, 100925
Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India
- 15 July 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 57, 100925
Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Clinical and Scientific Research
- Vol. 13 (4) , 314-316
Musings of a master clinician: Interesting students’ clinicopathological conference at Postgraduate Institute of Medical Education and Research, Chandigarh, on one of the Mondays in 1977
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of Clinical and Scientific Research
- Vol. 13 (4) , 314-316
Open AccessMusings of a master clinician: Interesting students’ clinicopathological conference at Postgraduate Institute of Medical Education and Research, Chandigarh, on one of the Mondays in 1977
- Open Access
- 7 September 2024
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 159 (6) , 585-600
Long COVID syndrome: An unfolding enigma
Post-acute sequelae of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease (COVID-19), called as long COVID syndrome, is a major global public health issue after recovery from COVID-19. The disease occurs in symptomatic patients irrespective of illness severity. The symptoms continue after four wk of recovery from acute illness and persist beyond three months. Risk factors for long COVID include older age, female gender, multiple co-morbidities including diabetes mellitus, prior chronic respiratory illnesses, hospitalized patients with severe disease, especially receiving assisted ventilation, high viral load, reactivation of Epstein Barr (EB) virus and human herpes virus 6 (HH6), circulating auto antibodies against various organs and type I interferon. The prevalence varies from 10 to 20 per cent, and most data have been reported from high-income countries. Any system can get involved in long COVID. The symptoms include fatigue, cognition impairment, cough and dyspnoea, anosmia, hair loss and diarrhoea, among others. While there are no laboratory tests for confirmation of diagnosis, reduced complement C7 complexes at six months, and a two-gene biomarker including FYN and SARS-CoV-2 antisense ribonucleic acid (RNA) are emerging as potentially useful biomarkers for long COVID. There should be no alternative disease to explain various symptoms. Vaccination against SARS-CoV-2 and early use of oral antiviral nirmatrelvir within the first five days in patients with acute mild disease having various risk factors for progression to severe disease help in preventing long COVID. Several clinical trials are underway for the treatment of long COVID and the results of these are eagerly awaited. Physical and mental rehabilitation at home, at community level or in the hospital setting as appropriate is essential in patients with long COVID.
- 7 September 2024
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 159 (6) , 585-600
Open AccessLong COVID syndrome: An unfolding enigma
Post-acute sequelae of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease (COVID-19), called as long COVID syndrome, is a major global public health issue after recovery from COVID-19. The disease occurs in symptomatic patients irrespective of illness severity. The symptoms continue after four wk of recovery from acute illness and persist beyond three months. Risk factors for long COVID include older age, female gender, multiple co-morbidities including diabetes mellitus, prior chronic respiratory illnesses, hospitalized patients with severe disease, especially receiving assisted ventilation, high viral load, reactivation of Epstein Barr (EB) virus and human herpes virus 6 (HH6), circulating auto antibodies against various organs and type I interferon. The prevalence varies from 10 to 20 per cent, and most data have been reported from high-income countries. Any system can get involved in long COVID. The symptoms include fatigue, cognition impairment, cough and dyspnoea, anosmia, hair loss and diarrhoea, among others. While there are no laboratory tests for confirmation of diagnosis, reduced complement C7 complexes at six months, and a two-gene biomarker including FYN and SARS-CoV-2 antisense ribonucleic acid (RNA) are emerging as potentially useful biomarkers for long COVID. There should be no alternative disease to explain various symptoms. Vaccination against SARS-CoV-2 and early use of oral antiviral nirmatrelvir within the first five days in patients with acute mild disease having various risk factors for progression to severe disease help in preventing long COVID. Several clinical trials are underway for the treatment of long COVID and the results of these are eagerly awaited. Physical and mental rehabilitation at home, at community level or in the hospital setting as appropriate is essential in patients with long COVID.
- Open Access
- 1 September 2021
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 154 (3) , 405-409
What is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?
- 1 September 2021
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 154 (3) , 405-409
Open AccessWhat is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?
- Top Cited Papers
- 3 July 2021
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 15 (7) , 931-948
Extrapulmonary tuberculosis
Introduction: Tuberculosis (TB) is a major cause of morbidity and mortality globally. Extrapulmonary TB (EPTB) constitutes about 15%-20% of all TB patients but accounts for 50% among HIV-coinfected. Confirmation of microbial diagnosis of EPTB is usually challenging. Areas covered: Availability of newer imaging modalities like 18FDG-PET-CT, PET-MRI, has facilitated precise anatomical localization of the lesions and mapping the extent of EPTB. The use of image-, endoscopy-guided invasive diagnostic methods has made procurement of tissue/body fluids for diagnostic testing possible. With the advent of universal drug-susceptibility testing, a rapid diagnosis of drug-resistance is now possible in EPTB. Drug-susceptible EPTB usually responds well to first-line anti-TB treatment; TB meningitis, bone and joint TB and lymph node TB often require longer duration of treatment. Expert opinion: Adjunctive use of corticosteroids in the initial period is recommended in central nervous system and pericardial TB. Surgical intervention is helpful to obtain tissue samples for diagnosis. Adjunctive surgical treatment along with medical treatment is useful in treating complications like hydrocephalus, Pott’s spine. Follow-up of EPTB patients is crucial as treatment is usually longer, requires recognition of development of immune reconstitution and inflammatory syndrome (IRIS), monitoring of adverse events, serious adverse events like anti-TB drug-induced hepatotoxicity, organ-related complications and treatment adherence.
- 3 July 2021
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 15 (7) , 931-948
Top Cited PapersExtrapulmonary tuberculosis
Introduction: Tuberculosis (TB) is a major cause of morbidity and mortality globally. Extrapulmonary TB (EPTB) constitutes about 15%-20% of all TB patients but accounts for 50% among HIV-coinfected. Confirmation of microbial diagnosis of EPTB is usually challenging. Areas covered: Availability of newer imaging modalities like 18FDG-PET-CT, PET-MRI, has facilitated precise anatomical localization of the lesions and mapping the extent of EPTB. The use of image-, endoscopy-guided invasive diagnostic methods has made procurement of tissue/body fluids for diagnostic testing possible. With the advent of universal drug-susceptibility testing, a rapid diagnosis of drug-resistance is now possible in EPTB. Drug-susceptible EPTB usually responds well to first-line anti-TB treatment; TB meningitis, bone and joint TB and lymph node TB often require longer duration of treatment. Expert opinion: Adjunctive use of corticosteroids in the initial period is recommended in central nervous system and pericardial TB. Surgical intervention is helpful to obtain tissue samples for diagnosis. Adjunctive surgical treatment along with medical treatment is useful in treating complications like hydrocephalus, Pott’s spine. Follow-up of EPTB patients is crucial as treatment is usually longer, requires recognition of development of immune reconstitution and inflammatory syndrome (IRIS), monitoring of adverse events, serious adverse events like anti-TB drug-induced hepatotoxicity, organ-related complications and treatment adherence.
- 3 July 2021
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 15 (7) , 949-958
Non-tuberculous mycobacteria: a disease beyond TB and preparedness in India
Fifty-six Indian studies on NTM diseases were selected between 1981-2020 from various electronic databases (PubMed, EMBASE, Medline, BIOSIS preview, and Scopus) for systematic review.NTM isolation ...
- 3 July 2021
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 15 (7) , 949-958
Non-tuberculous mycobacteria: a disease beyond TB and preparedness in India
Fifty-six Indian studies on NTM diseases were selected between 1981-2020 from various electronic databases (PubMed, EMBASE, Medline, BIOSIS preview, and Scopus) for systematic review.NTM isolation ...
- Open Access
- 1 December 2020
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 152 (6) , 667
Hiatus hernia resulting in interstitial lung fibrosis due to repeated gastro-oesophageal aspirations
- 1 December 2020
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 152 (6) , 667
Open AccessHiatus hernia resulting in interstitial lung fibrosis due to repeated gastro-oesophageal aspirations
- Open Access
- 1 November 2020
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 152 (Suppl 1) , S1-S3
Addison's disease due to histoplasmosis of bilateral adrenal glands in a previously treated extrapulmonary tuberculosis case
Indian J Med Res, Official publication of Indian Council of Medical Research,India
- 1 November 2020
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 152 (Suppl 1) , S1-S3
Open AccessAddison's disease due to histoplasmosis of bilateral adrenal glands in a previously treated extrapulmonary tuberculosis case
Indian J Med Res, Official publication of Indian Council of Medical Research,India